What Neuspera’s 12-month iSNM trial data means for the sacral neuromodulation competitive landscape

Neuspera Medical’s 12-month pivotal SNM trial shows 94% responder rates and zero infections. Analysing what this means for the SNM market. Read more.

Neuspera Medical’s 12-month pivotal SNM trial shows 94% responder rates and zero infections. Analysing what this means for the SNM market. Read more.